The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients

Highlights • VPA, an anticonvulsant with a narrow therapeutic range, is used to treat epilepsy. • UGT2B7 metabolizes VPA and has function missense mutations at C802T and G211T. • We investigated plasma VPA levels in C802T- and G211T-genotyped epilepsy patients. • Plasma VPA levels were influenced by...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Epilepsy research 2015-08, Vol.114, p.78-80
Hauptverfasser:	Sun, Yin-xiang, Zhuo, Wen-yan, Lin, Hong, Peng, Zheng-ke, Wang, Hua-ming, Huang, Hao-wu, Luo, Yu-hong, Tang, Fa-qing
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Alleles Anticonvulsants - pharmacokinetics Anticonvulsants - therapeutic use Asian Continental Ancestry Group Epilepsy Epilepsy - drug therapy Epilepsy - metabolism Female Genotype Glucuronosyltransferase - genetics Humans Male Neurology Polymorphism Polymorphism, Single Nucleotide Sex Characteristics UDP2B7 Valproic acid Valproic Acid - pharmacokinetics Valproic Acid - therapeutic use Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • VPA, an anticonvulsant with a narrow therapeutic range, is used to treat epilepsy. • UGT2B7 metabolizes VPA and has function missense mutations at C802T and G211T. • We investigated plasma VPA levels in C802T- and G211T-genotyped epilepsy patients. • Plasma VPA levels were influenced by the UGT2B7 C802T, but not the G211T, allele. • It may be necessary to increase the VPA dose in patients with a T allele at C802T.
ISSN:	0920-1211 1872-6844
DOI:	10.1016/j.eplepsyres.2015.04.015